Effects of gonadotropin-releasing hormone analogue on relationship between somatotropin axis function and growth velocity of girls with idiopathic central precocious puberty.

LIN Cui-lan,WEI Wan-jian,HE Wan-yi,LIU Yu-ling.

Chinese Journal of Child Health Care ›› 2016, Vol. 24 ›› Issue (1) : 65-67.

PDF(445 KB)
PDF(445 KB)
Chinese Journal of Child Health Care ›› 2016, Vol. 24 ›› Issue (1) : 65-67. DOI: 10.11852/zgetbjzz2016-24-01-19

Effects of gonadotropin-releasing hormone analogue on relationship between somatotropin axis function and growth velocity of girls with idiopathic central precocious puberty.

  • LIN Cui-lan,WEI Wan-jian,HE Wan-yi,LIU Yu-ling.
Author information +
History +

Abstract

Objective To recognize the effects and relationship between somatotropin axis function and growth velocity in girls with idiopathic central precocious puberty (ICPP) treated with gonadotropin-releasing hormone analogue (GnRHa),and provide a theoretical basis for new treatments to cure growth deceleration after GnRHa therapy. Methods A total of 27 girls with ICPP treated with GnRHa were studied prospectively.Their height,bone age (BA),serum insulin-like growth factor-1 (IGF-I) and IGF binding protein-3 (IGFBP-3) concentrations at the beginning and the end of one year of GnRHa treatment were measured.The standard deviation scores (SDSs) of their height,BA,IGF-I,and IGFBP-3 concentrations according to their age at the beginning and the end of one year of GnRHa treatment were calculated. Results After one-year GnRHa treatment,height SDS for CA(HtSDSCA) significantly decreased from 1.03±0.74 to 0.83±0.73 (P<0.001),but height SDS for BA(HtSDSBA) increased from (-0.56±0.78) to (-0.26±0.65) (P<0.001).There was no significant change in serum IGF-I SDS,IGFBP-3 SDS,and IGF-I/IGFBP-3 ratio(P>0.05).The advanced BA was the factor most strongly correlated to the height velocity (R=0.291,P<0.05). Conclusions There is no significant change in serum IGF-I SDS,IGFBP-3 SDS,and IGF-I/IGFBP-3 ratio after GnRHa treatment.The height velocity affected by GnRHa treatment may due to other mechanism than suppression of the IGF-I secretory axis.

Key words

central precocious puberty / gonadotropin-releasing hormone analogues / somatotropin axis / growth velocity

Cite this article

Download Citations
LIN Cui-lan,WEI Wan-jian,HE Wan-yi,LIU Yu-ling.. Effects of gonadotropin-releasing hormone analogue on relationship between somatotropin axis function and growth velocity of girls with idiopathic central precocious puberty.[J]. Chinese Journal of Child Health Care. 2016, 24(1): 65-67 https://doi.org/10.11852/zgetbjzz2016-24-01-19

References

[1] 中华人民共和国卫生部.性早熟诊疗指南(试行)【卫办医政发(195)号】[J].中国儿童保健杂志,2011,19(4):390-392.
[2] Gillis D,Karavani G,Hirsch HJ,et al.Time to menarche and final height after histrelin implant treatment for central precocious puberty[J].J Pediatr,2013,163(2):532-536.
[3] 马华梅.儿童性早熟药物治疗进展[J].实用儿科临床杂志,2011,26(8):553-557.
[4] Yi KH.Serum IGF-1 and IGFBP-3 levels in central precocious puberty girls treated with gonadotropin releasing hormone agonist (GnRHa) [J].J Korean Soc Pediatr Endocrinol,2011,16(3):20-23.
[5] 叶义言.中国儿童骨龄评分法[M].北京:人民卫生出版社,2005:11-55.
[6] 李辉,季成叶,张亚钦,等.中国0~18岁儿童身高体重的标准化生长曲线[J].中华儿科杂志,2009,47(7):487-492.
[7] 许珊珊,顾学范,潘慧,等.儿童青少年血清胰岛素生长因子-1及胰岛素因子结合蛋白-3的正常参考值研究[J].临床儿科杂志,2009,27(12):1105-1110.
[8] 中华医学会儿科分会内分泌遗传代谢学组青春发育调查研究协作组.中国九大城市女性儿童第二性征发育和初潮年龄调查[J].中华内分泌代谢杂志,2010,26(8):669-675.
[9] Yum T,Lee S,Kim Y.Association between precocious puberty and some endocrine disruptors in human plasma[J].J Environ Sci Health A Tox Hazard Subst Environ Eng,2013,48(8):912-917.
[10] Poli F,Pizza F,Mignot E,et al.High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy[J].Sleep,2013,36(2):175-181.
[11] Lee HS,Park HK,Ko JH,et al.Utility of Basal luteinizing hormone levels for detecting central precocious puberty in girls[J].Horm Metab Res,2012,44(11):851-854.
[12] Park HK,Lee HS,Ko JH,et al.The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty[J].Clin Endocrinol (Oxf),2012,77(5):743-748.
[13] 林小梅,文飞球,吴本清,等.性早熟女性患儿血清IGF-1和IGFBP-3质量浓度检测及临床价值[J].中国实用儿科杂志,2005,20(4):212-214.
[14] 马华梅,杜敏联.GnRHa对特发性中枢性性早熟女童生长的影响[J].中山大学学报:医学科学版,2003,24(2):156-160.
[15] Walvoord EC,Pescovitz OH.Combined use of growth hormone and gonadotropin-releasing hormone analogues in precocious puberty:theoretic and practical considerations[J].Pediatrics,1999,104(4Pt 2):1010-1014.
[16] Weise M,Flor A,Bames KM,et al.Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty[J].J Clin Endocrinol Metab,2004,89(1):103-107.
[17] Kim YJ,Lee HS,Lee YJ,et al.Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty[J].Ann Pediatr Endocrinol Metab,2013,18(4):173-178.
[18] Inman M,Hursh BE,Mokashi A,et al.Occurrence of slipped capital femoral epiphysis in children undergoing gonadotropin?releasing hormone agonist therapy for the treatment of central precocious puberty[J].Horm Res Paediatr,2013,80(1):64-68.
PDF(445 KB)

Accesses

Citation

Detail

Sections
Recommended

/